Filter by: patients
Home > Community Treatment Reports and Side Effects > Natalizumab Treatment Report
What is Natalizumab?

Natalizumab is a monoclonal antibody given by infusion and used in the treatment of MS and Crohn's disease. It has been shown to slow progression and reduce relapses in MS. It is currently sold under the brand name Tysabri.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
MS (Multiple Sclerosis) 1483 534 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Other 36 9 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Improve mobility 28 12 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Fatigue 22 11 Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
General health 22 6 Efficacy_major Efficacy_moderate Efficacy_none Efficacy_cant_tell
Stiffness/Spasticity 20 9 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none

See all 1410 patients currently taking Natalizumab

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 41
Moderate
 65
Mild
 161
None
 302

Commonly reported side effects, conditions, and hospitalizations associated with Natalizumab

Headaches 63
Tiredness 56
Fear of PML 25
Fatigue 20
Stomach pain 15
UTI symptoms 14
See all 199 reported side effects ▼ See top 6 reported side effects ▲

Reported Dosages

Frequently reported dosages based on patients currently taking Natalizumab. See all 33 dosages ►

  monthly 300mg/15mL as needed 1 other monthly 1 monthly 30 mg monthly 200 mg monthly 300 mg monthly 300 mg/15 mL monthly 300 mg/15 mL every 4 weeks 300 mg/15 mL daily
  136 Number of Patients: 136 7 Number of Patients: 7 3 Number of Patients: 3 4 Number of Patients: 4 3 Number of Patients: 3 4 Number of Patients: 4 40 Number of Patients: 40 521 Number of Patients: 521 653 Number of Patients: 653 13 Number of Patients: 13  

Reported Stop Reasons

Why Patients Stopped Taking Natalizumab (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice 138   Doctor's advice: 34%
Side effects too severe 130   Side effects too severe: 32%
Other 124   Other: 31%
Did not seem to work 96   Did not seem to work: 24%
Personal research 34   Personal research: 8%
Expense 21   Expense: 5%
Course of treatment ended 15   Course of treatment ended: 4%
Change in health plan coverage 11   Change in health plan coverage: 3%
Not indicated 3   Not indicated: 1%

See all 395 patients who’ve stopped taking Natalizumab

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Natalizumab

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Stopped Taking Natalizumab

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Natalizumab

Always
 526 92%
Usually
 29 5%
Sometimes
 2 0%
Never
 12 2%

Burden

Difficulty being on treatment

Burden of Natalizumab

Very
 29 5%
Somewhat
 77 14%
A little
 152 27%
Not at all
 311 55%

Cost

Paid out of pocket

Cost of Natalizumab

$200+
 94 23%
$100-199
 26 6%
$50-99
 36 9%
$25-49
 36 9%
< $25
 202 50%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 28, 2012.